Cambridge, MA The Bulfinch Companies, Inc. (Bulfinch) has signed a 114,490 s/f lease with FogPharma in building 400 at Cambridge Discovery Park (CDP). The lease marks the first signed tenant for Bulfinch’s new 400-500 property, a 280,000 s/f class A lab, R&D and office development. Peter Bekarian, managing director at Jones Lang LaSalle served as the broker on behalf of Bulfinch, and Evan Gallagher, senior vice president at Colliers International represented the tenant.
CDP towers 400 and 500 are LEED Gold buildings designed by Stantec, and located in an opportunity zone. The building was topped off in April and is set to deliver Q1 2020, with John Moriarty & Associates serving as general contractor. The property includes unobstructed views of Boston, a connector on the third through sixth floors over the private Discovery Way Dr., two lobbies and ground floor amenities including a café, fitness center, floor-to-ceiling windows and energy efficient systems. Situated in Alewife’s life science cluster, CDP has emerged as a desirable alternative to East Cambridge’s low vacancy constraints offering ample space for innovators in the city’s life science hub.
“We are thrilled that FogPharma has chosen to remain at CDP and expand in Building 400-500,” said Mike Wilcox, SVP, director of leasing at Bulfinch. “Bulfinch has enjoyed a close-working relationship with FogPharma for several years and looks forward to continued success for years to come. CDP provides an ideal location with flexibility for tenants to grow and expand their research long-term in a premier life science campus in Cambridge.”
As a current tenant in a 22,442 s/f space in Building 100 at CDP, FogPharma has leased all six floors of Building 400 with a phased move-in set to begin in January 2020. FogPharma will have an exclusive lobby in Building 400, exterior signage and branding rights to the building. FogPharma recognized the advantages of both location and amenities at CDP, electing to move into Building 400 to accommodate the company’s recent, expansive growth. For the first 3-5 years of the lease, FogPharma plans to sublet roughly half of its space in Building 400 to its sister company, LifeMine Therapeutics.
“FogPharma and LifeMine have grown in leaps and bounds since their operational start-up in 2016 and 2017, respectively. Our remarkable scientific progress demands continued aggressive growth to efficiently develop our pipeline of cell-penetrating miniproteins that engage the most intractable of disease targets,” said Greg Verdine Ph.D, president and CEO, FogPharma and LifeMine Therapeutics. “Fortunately, FogPharma and LifeMine are in a financial position to support our ambitious plans. It is both our pleasure and privilege to partner with Bulfinch once again to dramatically expand our presence in Cambridge Discovery Park, and together, foster the emergence of a vibrant biotech ecosystem in West Cambridge.”
As the third largest campus in the city behind Harvard and MIT, CDP offers a number of sustainable perks, including the surrounding Alewife Brook Reservation with 27 acres of walking trails and green space. While set in a natural location, CDP is easily accessible by foot or a short five-minute shuttle ride from the Alewife MBTA Red Line Station, off Rte. 2 and nine minutes from Rte. 128. CDP offers a 150-room AC Hotel Boston Cambridge with conference center, restaurant, bar and two 650-car covered parking garages. Other amenities at CDP include outdoor seating and dining areas, a full-service yoga and fitness center, an on-site café, multiple bike racks with a bike storage room, bike sharing, ATM banking, electric car charging stations and a new riverfront park with water sculpture. Two luxury residential developments are also under construction adjacent to CDP – Vox on 2 and the Residences at Alewife.
Notable tenants currently leasing in other CDP buildings include Forrester Research, Genocea Biosciences, Inc. and The Smithsonian Astrophysical Observatory.
